Retrospective Study
Copyright ©The Author(s) 2015.
World J Transplant. Sep 24, 2015; 5(3): 102-109
Published online Sep 24, 2015. doi: 10.5500/wjt.v5.i3.102
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Trends in the use of induction agents stratified by peak-panel reactive antibody in steroid maintenance (A) and early steroid withdrawal (B) groups. Alemtuzumab is used more commonly in steroid withdrawal group. r-ATG: Rabbit- antithymocyte globulin; PRA: Panel reactive antibody.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Over all adjusted graft (A-C) and death-censored graft (D-F) survivals in peak panel reactive antibody classes 0%-30%; 31%-60% and > 60% respectively. Note the association of steroid maintenance with decreased overall graft survival in the peak-PRA 0%-30% group and improved death-censored graft survival in peak-PRA > 60% group. PRA: Panel reactive antibody.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Adjusted patient survival (A-C) in peak-panel reactive antibody classes 0%-30%, 31%-60% and > 60% respectively. Note the inferior patient survival associated with steroid maintenance in peak-PRA groups 0%-30% and 31%-60%. PRA: Panel reactive antibody.